Two Sigma Investments LP Acquires 357,674 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Two Sigma Investments LP boosted its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 98.1% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 722,374 shares of the company's stock after purchasing an additional 357,674 shares during the period. Two Sigma Investments LP owned about 0.19% of GoodRx worth $3,359,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GDRX. National Bank of Canada FI raised its position in GoodRx by 34.9% during the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after acquiring an additional 2,151 shares in the last quarter. RPO LLC bought a new stake in GoodRx during the fourth quarter valued at about $52,000. Versor Investments LP acquired a new stake in shares of GoodRx in the fourth quarter valued at about $54,000. Verus Capital Partners LLC bought a new position in shares of GoodRx in the fourth quarter worth about $55,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in shares of GoodRx during the 4th quarter worth about $56,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Price Performance

Shares of GDRX stock traded up $0.07 during trading hours on Tuesday, hitting $3.89. The company had a trading volume of 100,666 shares, compared to its average volume of 1,371,638. GoodRx Holdings, Inc. has a 12 month low of $3.68 and a 12 month high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The firm's fifty day moving average is $4.28 and its 200 day moving average is $4.55. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of -129.67, a PEG ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.05. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The firm had revenue of $202.97 million for the quarter, compared to analysts' expectations of $202.25 million. During the same period in the prior year, the business posted $0.08 earnings per share. The business's revenue was up 2.6% compared to the same quarter last year. On average, sell-side analysts predict that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on GDRX. UBS Group lowered their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Truist Financial lowered their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Wells Fargo & Company cut their target price on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Finally, The Goldman Sachs Group decreased their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a research report on Friday, May 9th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $6.55.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.